The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer.

Sneha Deepak  Phadke

Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)

Menggang  Yu

Research Funding - Pfizer

Kathy  Miller

Consulting or Advisory Role - AstraZeneca; Athenex; Bristol-Myers Squibb/Celgene; Genentech/Roche; Merck

Research Funding - alphamab (Inst); Astex Pharmaceuticals (Inst); British Biotech (Inst); CytomX Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)

Ami N.  Shah

Consulting or Advisory Role - AstraZeneca/MedImmune

Oana Cristina  Danciu

Consulting or Advisory Role - Macrogenics

Research Funding - Pfizer; Sanofi

Kari Braun  Wisinski

Honoraria - Pfizer

Consulting or Advisory Role - AstraZeneca; Eisai; Eisai; Genomic Health; Novartis Institutes for BioMedical Research; Pfizer; Sanofi

Research Funding - AstraZeneca (Inst); Context Therapeutics (Inst); Genentech (Inst); Novartis (Inst); Oncoceutics (Inst); Pfizer; Pfizer; Sanofi (Inst)